Cargando…

Targeting the ileal bile salt transporter in the treatment of non-alcoholic fatty liver disease

Detalles Bibliográficos
Autor principal:	Jansen, Peter L. M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144141/ https://www.ncbi.nlm.nih.gov/pubmed/33523348 http://dx.doi.org/10.1007/s12072-021-10134-5

Ejemplares similares

Properties and biological significance of the ileal bile salt transport system.
por: Lack, L
Publicado: (1979)

Bile Acids and Dysbiosis in Non-Alcoholic Fatty Liver Disease
por: Mouzaki, Marialena, et al.
Publicado: (2016)

Bile acids and sphingolipids in non-alcoholic fatty liver disease
por: Jackson, Kaitlyn G., et al.
Publicado: (2022)

Non-Alcoholic Fatty Liver Disease: The Bile Acid-Activated Farnesoid X Receptor as an Emerging Treatment Target
por: Fuchs, Michael
Publicado: (2012)

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
por: Basheer, Maamon, et al.
Publicado: (2023)

The role of bile salts in liver regeneration
por: van de Laarschot, Liyanne F. M., et al.
Publicado: (2016)

The growing burden of non-alcoholic fatty liver disease on mortality
por: Cho, Ju-Yeon, et al.
Publicado: (2023)

Optimal diagnosis and management of non-alcoholic fatty liver disease
Publicado: (2022)

How to optimize the outcome of liver transplantation for non-alcoholic fatty liver disease
por: Song, Byeong Geun, et al.
Publicado: (2023)

Beyond Liver Disease: Non-Alcoholic Fatty Liver Disease and Advanced Liver Fibrosis in Kidney Disease
por: Han, Eugene
Publicado: (2022)

Non-invasive biomarkers for liver inflammation in non-alcoholic fatty liver disease: present and future
por: Chuah, Kee-Huat, et al.
Publicado: (2023)

Prevalence of frailty in patients with non-cirrhotic non-alcoholic fatty liver disease
por: O'Brien, Alastair
Publicado: (2022)

L-arginine conjugates of bile acids-a possible treatment for non-alcoholic fatty liver disease
por: Voloshin, Irina, et al.
Publicado: (2014)

Comparing the Mortality Risk between Metabolic Dysfunction-Associated Fatty Liver Disease and Non-Alcoholic Fatty Liver Disease
por: Jung, Han Na, et al.
Publicado: (2023)

Current and emerging pharmacological therapy for non-alcoholic fatty liver disease
por: Eshraghian, Ahad
Publicado: (2017)

Nutritional Intake and the Risk for Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Schattenberg, Jörn M., et al.
Publicado: (2019)

Managing non‐alcoholic fatty liver disease in diabetes: Challenges and opportunities
por: Lee, Chi‐Ho, et al.
Publicado: (2016)

An analysis of polygenic risk scores for non-alcoholic fatty liver disease
por: Jun, Dae Won
Publicado: (2021)

Bile Salts by the Back Road
por: Oude Elferink, Ronald P.J., et al.
Publicado: (2023)

Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future
por: Alnimer, Lynna, et al.
Publicado: (2023)

Should you advocate for hepatocellular carcinoma surveillance in patients with alcohol-related liver disease or non-alcoholic fatty liver disease?
por: Shim, Ju Hyun
Publicado: (2020)

Ileal Bile Acid Transporter Inhibition for the Treatment of Chronic Constipation, Cholestatic Pruritus, and NASH
por: Al-Dury, Samer, et al.
Publicado: (2018)

Targeting Liver X Receptors for the Treatment of Non-Alcoholic Fatty Liver Disease
por: Kim, Hyejin, et al.
Publicado: (2023)

From the liver to the heart: Cardiac dysfunction in obese children with non-alcoholic fatty liver disease
por: Di Sessa, Anna, et al.
Publicado: (2017)

Multi-disciplinary clinic models for the management of non-alcoholic fatty liver disease
por: Zoncapè, Mirko, et al.
Publicado: (2022)

The growing threat of non-alcoholic fatty liver disease-related hepatocellular carcinoma
por: Teng, Margaret L. P., et al.
Publicado: (2022)

Hepatocellular carcinoma surveillance in non-alcoholic fatty liver disease – who and how?
por: Teng, Margaret LP, et al.
Publicado: (2023)

Why Bile Acids Are So Important in Non-Alcoholic Fatty Liver Disease (NAFLD) Progression
por: Gottlieb, Aline, et al.
Publicado: (2019)

The Role of Gut Microbiota-Bile Acids Axis in the Progression of Non-alcoholic Fatty Liver Disease
por: Ni, Yiming, et al.
Publicado: (2022)

Treatment of non-alcoholic fatty liver disease
por: Tolman, Keith G, et al.
Publicado: (2007)

Editorial: International Consensus Recommendations to Replace the Terminology of Non-Alcoholic Fatty Liver Disease (NAFLD) with Metabolic-Associated Fatty Liver Disease (MAFLD)
por: Méndez-Sánchez, Nahum, et al.
Publicado: (2021)

What's in a disease like non‐alcoholic fatty liver disease—East versus West?
por: Dan, Yock Young
Publicado: (2022)

Hepatocellular Carcinoma and Non-Alcoholic Fatty Liver Disease: A Modern Context for an Ancient Disease
por: Gallo, Paolo, et al.
Publicado: (2023)

Quantitative imaging tests for non-alcoholic fatty liver disease: which, when and why
por: Dennis, Andrea
Publicado: (2023)

Screening strategies for non-alcoholic fatty liver disease: a holistic approach is needed
por: Kasper, Philipp, et al.
Publicado: (2023)

Biological tuners to reshape the bile acid pool for therapeutic purposes in non-alcoholic fatty liver disease
por: Gillard, Justine, et al.
Publicado: (2023)

The Crosstalk between Gut Microbiota and Bile Acids Promotes the Development of Non-Alcoholic Fatty Liver Disease
por: Li, Zhonglin, et al.
Publicado: (2023)

The Importance of the Fatty Acid Transporter L-Carnitine in Non-Alcoholic Fatty Liver Disease (NAFLD)
por: Savic, Dragana, et al.
Publicado: (2020)

Pediatric non alcoholic fatty liver disease: more on novel treatment targets
por: Vajro, Pietro, et al.
Publicado: (2013)

Docosahexaenoic acid and non-alcoholic fatty liver disease in obese children: a novel approach?
por: Verduci, Elvira, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_a4p46r8dfasesfqtq6fo309dv0